Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Gastrointestinal Stromal Tumors Clinical Trial

Official title:

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00688766
• Other study ID #: IPI-504-06
• Status: Terminated
• Phase: Phase 3
• First received: May 29, 2008
• Last updated: December 7, 2012
• Start date: August 2008
• Est. completion date: May 2009

Study information

• Verified date: December 2012
• Source: Infinity Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

IPI-504-06 is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of IPI-504 as compared to placebo in patients with metastatic and/or unresectable GIST following failure of at least imatinib and sunitinib.

Approximately 195 patients will be randomized using a 2:1 ratio to receive either IPI-504 (N=130) or placebo (N=65). Upon unblinding, patients receiving either IPI-504 or placebo may receive IPI-504 in the open-label portion of the study if defined inclusion criteria are met.

Early and frequent imaging timepoints (Weeks 2, 5, 8, 14 and every 6 weeks thereafter) are incorporated into this study to capture progression events and limit patient exposure to ineffective agents.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 47
• Est. completion date: May 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years of age at the time of study randomization.

• Histologically confirmed metastatic and/or unresectable GIST.

• Measurable disease on CT or MRI as defined by RECIST.

• Documented radiographic progression or intolerance to imatinib and sunitinib.

• Clinical failure of the most recent prior therapy for GIST. Note: There is no limit to the number of prior therapies a patient may have received.

• Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.

• Hemoglobin = 8.0 g/dL (80 g/L).

• Absolute Neutrophil Count = 1500/µL (1.5 x 109/L).

• Platelets = 100,000 /µL (100 x 109/L).

• ALT and AST = 2.5 x upper limit of normal (ULN), or = 5.0 x ULN if considered secondary to liver metastases.

• Alkaline phosphatase = 2.5 x ULN, or = 5.0 x ULN if considered secondary to liver metastases.

• Serum bilirubin = 1.5 x ULN.

• PT and PTT = 1.5 x ULN unless the patient is receiving warfarin. If the patient is receiving warfarin, the INR must be within therapeutic range.

• Serum creatinine = 1.5 x ULN.

Exclusion Criteria:

• Previous administration of other known heat shock protein 90 (Hsp90) inhibitors.

• Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease.

• Initiation or discontinuation of concurrent medication that is a potent CYP3A inhibitor less than 2 weeks prior to administration of IPI-504 or placebo.

• History of any of the following within the last 6 months: cardiac disease such as acute coronary syndrome or unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or any other significant co-morbid condition or disease which, in the judgment of the investigator, would place the patient at undue risk or interfere with the study.

• Grade 3 or 4 hemorrhagic event within the last 6 months.

• Known human immunodeficiency virus positivity.

• Sinus bradycardia (resting heart rate < 50 bpm) secondary to intrinsic conduction system disease.

• QTcF = 470 milliseconds, or previous history of clinically significant QTc prolongation while taking other medications.

• History of prior malignancies within the past 3 years other than non-melanomatous skin cancers that have been controlled, prostate cancer that has been treated and has not recurred, non-muscle-invasive bladder cancer, and carcinoma in situ of the cervix.

• Active or recent history (within 3 months) of keratitis or keratoconjunctivitis confirmed by ophthalmology or optometry exam.

• Presence of Left Bundle Branch Block, Right Bundle Branch Block plus left anterior hemiblock, bifascicular block, or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.

• Known CNS metastases.

• Women who are pregnant or lactating.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gastrointestinal Stromal Tumors

Intervention

Drug:
• retaspimycin hydrochloride (IPI-504)
IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
• placebo
Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.

Other:
• Best supportive care
Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Infinity Pharmaceuticals, Inc.	AstraZeneca, MedImmune LLC

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare the progression free survival (PFS) in both study arms		Multiple timepoints	No
Secondary	Compare the disease control rate (DCR) in both arms		Multiple timepoints	No
Secondary	Compare the time to progression (TTP) in both arms		Multiple timepoints	No
Secondary	Compare the overall survival (OS) in both arms		Continuous	No
Secondary	Evaluate the safety and tolerability of IPI-504 in this patient population		Signing of the informed consent to 30 days after discontinuation of drug	Yes

External Links

•   Gist Support International - Patient Advocacy Group
•   The Liferaft Group - Patient Advocacy Group